Prognostic significance of bcl9 expression in hepatocellular carcinoma

Korean Journal of Pathology

Volumn 47, Issue 2, 2013, Pages 130-136

  Hyeon, Jiyeon ^a   Ahn, Soomin ^a   Lee, Jae Jun ^a   Song, Dae Hyun ^a   Park, Cheol Keun ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

BCL9; Carcinoma; Hepatocellular; Recurrence; Survival

Indexed keywords

EID: 84879198885     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: 10.4132/KoreanJPathol.2013.47.2.130     Document Type: Article

References (19)

1. Poon RT. Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge. Hepatology 2011; 54: 757-9.
2. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200.
3. Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 2004; 130: 497-513.
4. Willis TG, Zalcberg IR, Coignet LJ, et al. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 1998; 91: 1873-81.
5. Kramps T, Peter O, Brunner E, et al. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear betacatenin- TCF complex. Cell 2002; 199: 47-60.
6. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837-51.
7. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-90.
8. Mani M, Carrasco DE, Zhang Y, et al. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res 2009; 69: 7577-86.
9. Brembeck FH, Wiese M, Zatula N, et al. BCL9-2 promotes early stages of intestinal tumor progression. Gastroenterology 2011; 141: 1359- 70.
10. Kim TM, Yim SH, Shin SH, et al. Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int J Cancer 2008; 123: 2808-15.
11. Moinzadeh P, Breuhahn K, Stützer H, Schirmacher P. Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade: results of an explorative CGH metaanalysis. Br J Cancer 2005; 92: 935-41.
12. Wong N, Lai P, Lee SW, et al. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol 1999; 154: 37-43.
13. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 190 cases among 48,900 necropsies. Cancer 1954; 7: 462-503.
14. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. 2nd ed. Tokyo: Kanehara, 2003; 38.
15. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A 3rd. AJCC cancer staging manual. 7th ed. Chicago: Springer, 2019.
16. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
17. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.
18. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 22: 983-93.
19. Kim SH, Ahn S, Park CK. Smad3 and its phosphoisoforms are prognostic predictors of hepatocellular carcinoma after curative hepatectomy. Hepatobiliary Pancreat Dis Int 2012; 11: 51-9